콘텐츠로 건너뛰기
Merck
  • A lncRNA signature associated with tumor immune heterogeneity predicts distant metastasis in locoregionally advanced nasopharyngeal carcinoma.

A lncRNA signature associated with tumor immune heterogeneity predicts distant metastasis in locoregionally advanced nasopharyngeal carcinoma.

Nature communications (2022-06-01)
Ye-Lin Liang, Yuan Zhang, Xi-Rong Tan, Han Qiao, Song-Ran Liu, Ling-Long Tang, Yan-Ping Mao, Lei Chen, Wen-Fei Li, Guan-Qun Zhou, Yin Zhao, Jun-Yan Li, Qian Li, Sheng-Yan Huang, Sha Gong, Zi-Qi Zheng, Zhi-Xuan Li, Ying Sun, Wei Jiang, Jun Ma, Ying-Qin Li, Na Liu
초록

Increasing evidence has revealed the roles of long noncoding RNAs (lncRNAs) as tumor biomarkers. Here, we introduce an immune-associated nine-lncRNA signature for predicting distant metastasis in locoregionally advanced nasopharyngeal carcinoma (LA-NPC). The nine lncRNAs are identified through microarray profiling, followed by RT-qPCR validation and selection using a machine learning method in the training cohort (n = 177). This nine-lncRNA signature classifies patients into high and low risk groups, which have significantly different distant metastasis-free survival. Validations in the Guangzhou internal (n = 177) and Guilin external (n = 150) cohorts yield similar results, confirming that the signature is an independent risk factor for distant metastasis and outperforms anatomy-based metrics in identifying patients with high metastatic risk. Integrative analyses show that this nine-lncRNA signature correlates with immune activity and lymphocyte infiltration, which is validated by digital pathology. Our results suggest that the immune-associated nine-lncRNA signature can serve as a promising biomarker for metastasis prediction in LA-NPC.

MATERIALS
제품 번호
브랜드
제품 설명

Sigma-Aldrich
Anti-MS4A1 antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution